Imagine discovering that a silent invader has been wreaking havoc on your brain for years, long before you even notice any symptoms. That's the chilling reality of multiple sclerosis (MS), a disease that stealthily damages the brain far earlier than previously thought. But here's where it gets even more startling: recent research reveals that the immune system starts its attack on the brain much sooner than anyone realized, potentially opening the door to groundbreaking ways to diagnose—and maybe even prevent—this debilitating condition.
Scientists at UC San Francisco have made a remarkable breakthrough by analyzing thousands of proteins in the blood, painting the clearest picture yet of how MS progresses. Published in Nature Medicine (https://www.nature.com/articles/s41591-025-04014-w), their study tracks the sequence of events leading to the disease, starting with the immune system’s assault on the myelin sheath—the protective fatty layer around nerve fibers. Astonishingly, this damage begins years before patients experience symptoms or seek treatment.
And this is the part most people miss: the researchers identified a protein called IL-3 that plays a starring role in this early phase. IL-3 recruits immune cells to the brain and spinal cord, where they mistakenly attack nerve cells. This happens silently, long before patients feel any effects. Another protein, MOG (myelin oligodendrocyte glycoprotein), spikes in the blood up to seven years before diagnosis, signaling damage to the myelin sheath. A year later, a protein called neurofilament light chain appears, indicating that the nerve fibers themselves are breaking down.
By analyzing over 5,000 proteins in blood samples from 134 people with MS—both before and after their diagnosis—the team uncovered about 50 proteins that could predict the disease. They’ve even filed a patent application for a diagnostic blood test using the top 21 of these proteins. This could revolutionize how MS is detected and managed, potentially catching it before irreversible damage occurs.
“We think our work opens numerous opportunities for diagnosing, monitoring, and possibly treating MS,” said Dr. Ahmed Abdelhak, lead author of the study and assistant professor of Neurology at UCSF. “It could be a gamechanger for how we understand and manage this disease.”
But here’s the controversial part: If MS begins so much earlier than symptoms appear, should we start screening people for these proteins as a routine part of healthcare? And if we can predict who might develop MS, are we prepared to handle the ethical implications of such knowledge? These questions spark heated debates among experts and patients alike.
Dr. Ari Green, senior author of the study and chief of the Division of Neuroimmunology and Glial Biology at UCSF, emphasized the transformative potential of these findings. “We now know that MS starts way earlier than the clinical onset, creating the real possibility that we could someday prevent MS—or at least use our understanding to protect people from further injury,” he said.
This research not only deepens our understanding of MS but also offers hope for a future where the disease can be stopped before it starts. But what do you think? Should we push for widespread screening, or is it too early to tell? Share your thoughts in the comments—this is a conversation that needs your voice.
